In a retrospective analysis by Kubota et al. [35], 63 patients with T2DM on usual doses of SGLT2-i (Empagliflozin, Canagliflozin, Dapagliflozin, or Tofogliflozin), showed a significant decrease in total cholesterol and non-HDL-C levels, but no changes in TG, HDL, or LDL-C levels. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.